Vaccines and the Biotechnology Industry · global
Enterovirus 71 Vaccine Expands into Southeast Asia: Duopharma Secures Exclusive Distribution Rights in Three Countries
Taiwan’s Enimmune will bring its EnVAX-A71 vaccine to Malaysia, Singapore and Brunei through a new partnership. The distribution agreement is in place, but local regulatory and market hurdles remain between obtaining marketing authorization and supplying the vaccine.
One key aspect of preventing hand, foot and mouth disease is reducing the risk of severe illness in young children who become infected. Malaysia’s Duopharma Biotech has signed a cooperation agreement with Taiwan’s Enimmune to introduce EnVAX-A71, a vaccine targeting enterovirus 71, into regional markets. However, this development establishes a framework for commercial cooperation and applications for marketing authorization; regulatory approvals in all three countries have yet to be obtained.
On October 15, The Edge Malaysia cited a stock exchange filing reporting that Duopharma’s wholly owned subsidiary, Duopharma (M) Sdn Bhd, had secured exclusive distribution rights for the vaccine in Malaysia, Singapore and Brunei and would be responsible for seeking local approvals. Enimmune will cover costs related to good manufacturing practice (GMP) assessments and support launch marketing in Malaysia. If a country refuses approval, the distributor’s contractual obligations in that country will end.
EnVAX-A71 is an inactivated monovalent vaccine targeting enterovirus A71 (EV-A71, also known as enterovirus 71). This virus can cause hand, foot and mouth disease, with a small proportion of infected individuals developing neurological complications such as encephalitis. However, hand, foot and mouth disease can also be caused by other enteroviruses, including coxsackieviruses, so this vaccine’s protection should not be interpreted as covering all hand, foot and mouth disease.
Its clinical basis comes from a randomized, double-blind, placebo-controlled Phase 3 trial conducted in Taiwan and Vietnam, which enrolled 4,011 young children aged 2 to 71 months. A study published this year in npj Vaccines reported that, in the primary analysis population, there was 1 case of laboratory-confirmed EV-A71-associated hand, foot and mouth disease or herpangina in the vaccine group, compared with 70 cases in the placebo group, yielding an estimated vaccine efficacy of 99.2%. These data concern a specific virus and trial endpoint and do not mean that the vaccine provides the same level of protection against all enterovirus diseases.
The contract also translates market demand into explicit performance requirements. According to The Edge Malaysia, the cooperation term in each market runs separately through the fifth anniversary of the local launch date, with minimum annual order quantities. If orders fall below 70% of the minimum requirement for two consecutive contract years, Enimmune has the right to terminate the agreement. The continuation of distribution rights therefore also depends on actual purchasing after approval.
CodeBlue’s October 16 report outlined a longer-term direction for the partnership: Duopharma hopes to expand its portfolio through Enimmune’s vaccine technology, support and facilities, while seeking opportunities to collaborate on subsequent vaccine pipeline candidates. The company also mentioned exploring the possibility of local manufacturing in Malaysia, provided demand is sufficient and it is commercially viable. This cannot yet be regarded as a confirmed plan to establish a manufacturing facility or transfer technology.
For families and healthcare systems, the distribution partnership is only one step toward vaccine access. Existing reports have yet to specify exact launch timelines, prices or public procurement arrangements in the three countries. The populations ultimately eligible for vaccination and the conditions of use will also depend on local approvals. This agreement establishes a pathway for regional supply, but whether it translates into actual access still depends on the regulatory reviews and supply arrangements ahead.